Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment.
• They offer targeted delivery of potent cytotoxic agents to tumor cells, enhancing efficacy and reducing systemic toxicity.
• ADCs are effective in both hematologic malignancies and solid tumors.

Purpose of the Study:

• To review the fundamental biology of antibody-drug conjugates.
• To discuss the evolving landscape of ADC applications, including earlier-stage disease and combination therapies.
• To highlight critical considerations for patient selection and toxicity management in the expanding use of ADCs.

Main Methods:

• Literature review of antibody-drug conjugate biology and clinical applications.
• Analysis of current trends and future directions in ADC development and clinical practice.
• Synthesis of information on patient stratification and adverse event management.

Main Results:

• Antibody-drug conjugates demonstrate broad applicability and growing clinical success.
• The field is expanding towards earlier lines of therapy and combination regimens.
• Effective patient selection and robust toxicity management are crucial for optimizing ADC outcomes.

Conclusions:

• Antibody-drug conjugates are a cornerstone of modern anticancer therapy.
• Future research should focus on refining patient selection criteria and managing toxicities associated with novel ADC combinations and earlier-stage applications.
• Continued innovation in ADC technology and clinical strategy is essential for maximizing patient benefit.